Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Nurs Outlook ; 60(3): 149-156.e1-3, 2012.
Article in English | MEDLINE | ID: mdl-22172370

ABSTRACT

Translational clinical research has emerged as an important priority for the national research enterprise, with a clearly stated mandate to more quickly deliver prevention strategies, treatments and cures based on scientific innovations to the public. Within this national effort, a lack of consensus persists concerning the need for clinical nurses with expertise and specialized training in study implementation and the delivery of care to research participants. This paper reviews efforts to define and document the role of practicing nurses in implementing studies and coordinating clinical research in a variety of clinical settings, and differentiates this clinical role from the role of nurses as scientists and principal investigators. We propose an agenda for building evidence that having nurses provide and coordinate study treatments and procedures can potentially improve research efficiency, participant safety, and the quality of research data. We also provide recommendations for the development of the emerging specialty of clinical research nursing.


Subject(s)
Clinical Nursing Research/organization & administration , Nurse's Role , Translational Research, Biomedical/organization & administration , Clinical Nursing Research/standards , Evidence-Based Practice , Financing, Government , Humans , Internationality , Research Support as Topic , Specialties, Nursing , Translational Research, Biomedical/economics , United States
2.
Urology ; 44(4): 525-9, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7524238

ABSTRACT

OBJECTIVES: To determine if tissue expression of prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), and a prostate-associated monoclonal antibody (TURP-27) is retained after irradiation therapy and to compare these results with serum levels. METHODS: Immunohistochemical tests were performed on prostatic tissue obtained by needle biopsy or transurethral resection prior to and following definitive irradiation therapy for clinically localized prostatic carcinoma. PSA, PAP, and TURP-27 were studied. Results were compared with serum PSA and PAP values. RESULTS: All 20 preirradiation specimens stained positively for PSA and PAP; 19 of 20 stained for TURP-27. All 5 of the initial post-treatment biopsy specimens that showed recurrent tumor stained for all 3 markers. In 2 cases, staining for the 3 markers was greatly diminished. Only 8 of 15 post-treatment biopsy-negative specimens stained for all 3 markers. Six of 15 demonstrated loss of tissue expression for all 3 antigens. One specimen stained for PAP and TURP-27 but failed to stain for PSA. Serum PSA levels paralleled tissue expression in recurrent tumor specimens. However, 3 of the post-treatment biopsy-positive cases with PAP expressing tissue had normal serum PAP levels. CONCLUSIONS: No cases of recurrent tumor with marker-negative tissue were identified. However, benign epithelial prostate cells appear to sustain sufficient damage from irradiation to lose the capacity to produce certain proteins. Diminished contribution of benign glands to circulating PSA, in addition to decreased expression in malignant tissues, may explain the lower than anticipated serum PSA levels in patients who progress after irradiation therapy.


Subject(s)
Acid Phosphatase/metabolism , Adenocarcinoma/metabolism , Antigens, Neoplasm/metabolism , Biomarkers, Tumor/metabolism , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/metabolism , Acid Phosphatase/radiation effects , Adenocarcinoma/pathology , Adenocarcinoma/radiotherapy , Antibodies, Monoclonal , Antigens, Neoplasm/radiation effects , Biomarkers, Tumor/radiation effects , Biopsy, Needle , Humans , Immunoenzyme Techniques , Male , Prostate/metabolism , Prostate/pathology , Prostate/radiation effects , Prostate-Specific Antigen/radiation effects , Prostatic Neoplasms/pathology , Prostatic Neoplasms/radiotherapy , Staining and Labeling , Time Factors
3.
Prostate ; 23(3): 201-12, 1993.
Article in English | MEDLINE | ID: mdl-7694265

ABSTRACT

Serum prostate secretory protein (PSP) levels were measured in 49 patients with benign prostatic hyperplasia (BPH), 144 patients with various stages of prostatic carcinoma (CaP), and 82 CaP patients who were followed serially. PSP values were compared with serum levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP). In the BPH group, PSP was elevated (> 10 ng/ml) in 41% of patients, whereas PSA (> 4 ng/ml) and PAP (> 3.3 ng/ml) were elevated in 39% and 23% of the cases, respectively. PSP levels were elevated in 48% of the CaP pretreatment specimens, compared to 79% for PSA and 40% for PAP. PSP levels in cancer patients who had intracapsular disease were about two to three times higher than those observed for PAP. PSP was found to be the only marker elevated in eight (6%) pretreatment CaP patient serum specimens, while PAP was never found to be elevated when PSA was normal. PSP serum concentrations correlated with the clinical course of the disease in 79% of patients, compared with 90% for PSA and 66% for PAP. In certain patients, monitored over time, disease correlation was reflected in serum values with only a single biomarker, i.e., 1% with PAP, 8% with PSP, and 10% with PSA. This study has shown that PSP is a less sensitive serum biomarker than PSA, but more sensitive than PAP for detection and monitoring the early stages of prostate cancer. This suggests that PSP as a biomarker may be a useful adjunct for the management of a subpopulation of low-stage and -grade CaP.


Subject(s)
Acid Phosphatase/blood , Biomarkers/blood , Carrier Proteins/blood , Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Prostatic Secretory Proteins , Humans , Male , Predictive Value of Tests , Prostate/metabolism , Prostatic Hyperplasia/blood , Prostatic Neoplasms/diagnosis , Sensitivity and Specificity
4.
Clin Chem ; 38(6): 817-23, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1375876

ABSTRACT

We developed a double-determinant immunoradiometric assay for measuring serum prostate secretory protein (PSP), using monoclonal antibodies (MAb) against two different epitopes: MAb PSP-19 was the capture antibody and MAb PSP-6 was the tracer antibody. Assay sensitivity was 0.1 microgram/L. Analytical recovery of PSP was 93.5-104.6%, whereas the intra- and interassay mean CVs were 4.2% and 6.9%, respectively. In 92 normal men, ages greater than 50 years, the mean PSP concentration was 5.7 micrograms/L, with 10 (10.9%) men having concentrations greater than 10 micrograms/L. In contrast, 20 of 49 (40.8%) patients with benign prostate hyperplasia (BPH; mean PSP concentration 9.4 micrograms/L) and 46 of 100 (46%) patients with prostate cancer (mean PSP concentration 22.2 micrograms/L) had PSP concentrations greater than 10 micrograms/L. Mean serum PSP concentrations of the BPH (P less than 0.05) and prostate cancer (P less than 0.01) groups were significantly different from those of age-matched normal men. In a small group of patients, serial PSP concentrations correlated with the clinical course during therapy. Thus, PSP may be a useful marker for evaluating patients with prostate cancer.


Subject(s)
Antibodies, Monoclonal , Carrier Proteins/blood , Immunoradiometric Assay , Prostatic Secretory Proteins , Female , Freezing , Humans , Immunoradiometric Assay/standards , Immunoradiometric Assay/statistics & numerical data , Male , Menopause , Middle Aged , Pregnancy , Prostatic Hyperplasia/blood , Prostatic Neoplasms/blood , Quality Control , Reference Values
5.
J Urol ; 145(5): 1008-10; discussion 1010-1, 1991 May.
Article in English | MEDLINE | ID: mdl-1707987

ABSTRACT

Prostate specific antigen (PSA) levels were determined in 78 patients judged clinically to be free of disease at intervals of 36 or more months (range 38 to 186 months, median 87 months) after completion of irradiation therapy by 125iodine implantation or external beam radiation. Of this select group of patients 38% had undetectable serum PSA levels (0.5 ng./ml. or less) and 38% had PSA levels that were within normal limits (4.0 ng./ml. or less). All stages and grades were represented. Undetectable PSA levels were only rarely found (3%) in patients with carcinoma of the prostate before treatment. In 24 of these 78 patients a negative biopsy of the irradiated prostate had been obtained 18 to 42 months after treatment. When the PSA level was drawn, which ranged from 7 to 16 years after treatment, an equal percentage of these biopsied patients had either an undetectable, normal or elevated level. Irradiation is able to decrease PSA to undetectable levels in some patients with prostatic carcinoma. Whether this reflects suppression of marker production alone or, more importantly, ablation of prostate cancer producing that marker remains to be determined.


Subject(s)
Antigens, Neoplasm/blood , Biomarkers, Tumor/blood , Prostatic Neoplasms/radiotherapy , Acid Phosphatase/blood , Brachytherapy , Follow-Up Studies , Humans , Iodine Radioisotopes/therapeutic use , Male , Prostate/chemistry , Prostate-Specific Antigen , Prostatic Neoplasms/blood , Radioimmunoassay , Radiotherapy, High-Energy , Time Factors
6.
Clin Chem ; 27(10): 1747-52, 1981 Oct.
Article in English | MEDLINE | ID: mdl-6169470

ABSTRACT

We evaluated and compared five commercial radioimmunoassay kits with a standard counter-immunoelectrophoretic assay for the measurement of prostatic acid phosphatase in serum. Four of the five radioimmunoassays performed as described by the supplier with respect to sensitivity, stability, precision, linearity, analytical recovery, and expected values for the normal male population. None of the radioimmunoassays was more clinically sensitive then the counter-immunoelectrophoretic assay for detecting increased prostatic acid phosphatase in serum. Results obtained by counter-immunoelectrophoretic assay agreed with results obtained by radioimmunoassay in 96% of the tests. The proportion of positive results in patients with confirmed prostatic adenocarcinoma increased with disease progression. The fewer positive tests in localized adenocarcinoma (Stages A and B) suggests that neither the counter-immunoelectrophoretic assay nor the radioimmunoassay procedures are useful for screening unselected populations for adenocarcinoma of the prostate. The high percentage of normal values found in those patients clinically free of disease after treatment is encouraging and supports the use of the prostatic acid phosphatase immunoassays in prospectively monitoring the treatment of prostatic cancer patients.


Subject(s)
Acid Phosphatase/blood , Counterimmunoelectrophoresis/methods , Immunoelectrophoresis/methods , Prostate/enzymology , Adenocarcinoma/enzymology , Adult , Aged , Humans , Male , Middle Aged , Prostatic Hyperplasia/enzymology , Prostatic Neoplasms/enzymology , Radioimmunoassay/methods , Reagent Kits, Diagnostic
7.
Prostate ; 2(2): 121-31, 1981.
Article in English | MEDLINE | ID: mdl-6170963

ABSTRACT

The leukocyte migration inhibition (LMI) assay was used to determine the cell-mediated immune reactivity of prostate cancer patients to putative tumor antigens present in potassium chloride extracts of surgically removed prostate tumor tissue. Using an extract prepared from prostate tumor tissue, inhibition of leukocyte migration was found more frequently in prostate tumor patients (61%) than in patients with benign prostate hyperplasia (37%), patients with nonprostate cancers (26%), or normal donors (10%). Control extracts prepared from normal prostate tissue, benign prostate hyperplasia tissue, and unrelated tumor tissue were statistically less reactive in the LMI assay than the prostate tumor extract when reacted against leukocytes from prostate tumor patients. These results suggest that the LMI assay might be potentially useful for measuring the tumor-directed, cell-mediated immune responses in patients with prostate cancer.


Subject(s)
Adenocarcinoma/immunology , Antigens, Neoplasm/immunology , Cell Migration Inhibition , Leukocytes/immunology , Prostatic Neoplasms/immunology , Adenocarcinoma/blood , Adult , Aged , Humans , Immunity, Cellular , Male , Middle Aged , Neoplasms/immunology , Prostatic Hyperplasia/immunology , Prostatic Neoplasms/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...